tiprankstipranks
Advertisement
Advertisement

ANRO Stock Latest News

Alto Neuroscience Raises Capital to Advance ALTO-207
Company AnnouncementsAlto Neuroscience Raises Capital to Advance ALTO-207
10d ago
8K
ANRO
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials
PremiumCompany Announcements
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials
12d ago
8K
ANRO
Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering
PremiumThe Fly
Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering
12d ago
ANRO
Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
PremiumThe Fly
Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
1M ago
ANRO
Alto Neuroscience Appoints Andrew Miller to Board
PremiumCompany Announcements
Alto Neuroscience Appoints Andrew Miller to Board
2M ago
8K
ANRO
Alto Neuroscience appoints Miller to Board of Directors
PremiumThe FlyAlto Neuroscience appoints Miller to Board of Directors
2M ago
ANRO
Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target
Premium
Ratings
Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target
2M ago
ANRO
Alto Neuroscience price target lowered to $33 from $35 at BofA
Premium
The Fly
Alto Neuroscience price target lowered to $33 from $35 at BofA
2M ago
ANRO
Alto Neuroscience price target lowered to $36 from $38 at Baird
PremiumThe Fly
Alto Neuroscience price target lowered to $36 from $38 at Baird
2M ago
ANRO
Alto Neuroscience price target raised to $24 from $21 at Wedbush
PremiumThe Fly
Alto Neuroscience price target raised to $24 from $21 at Wedbush
2M ago
ANRO
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
PremiumRatings
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
2M ago
ANRO
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
PremiumRatings
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
2M ago
ANRO
Alto Neuroscience Shareholders Shape Governance and Equity Plans
PremiumCompany AnnouncementsAlto Neuroscience Shareholders Shape Governance and Equity Plans
2M ago
8K
ANRO
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
Premium
The Fly
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
2M ago
ANRO
Alto Neuroscience initiated with a Buy at BofA
Premium
The Fly
Alto Neuroscience initiated with a Buy at BofA
3M ago
ANRO
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
PremiumThe Fly
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
3M ago
ANRO
Alto Neuroscience participates in a conference call with H. C. Wainwright
PremiumThe Fly
Alto Neuroscience participates in a conference call with H. C. Wainwright
3M ago
ANRO
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
PremiumThe Fly
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
3M ago
ANRO
Alto Neuroscience files to sell 6M shares of common stock for holders
PremiumThe Fly
Alto Neuroscience files to sell 6M shares of common stock for holders
4M ago
ANRO
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
PremiumThe FlyAlto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
4M ago
ANRO
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
Premium
The Fly
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
4M ago
ANRO
Morning Movers: Immunovant sinks after batoclimab trials miss goal
Premium
The Fly
Morning Movers: Immunovant sinks after batoclimab trials miss goal
4M ago
BP
ALK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >